248 related articles for article (PubMed ID: 26674803)
1. Vehicle Systems and Excipients Used in Minipig Drug Development Studies.
Weaver ML; Grossi AB; Schützsack J; Parish J; Løgsted J; Bøgh IB; Cameron D; Harvey W; Festag M; Downes N; Venturella S; Schlichtiger J; Mhedhbi S; Ross V; Kissner T; Stark C; Milano S; Heining P; Sanchez-Felix M
Toxicol Pathol; 2016 Apr; 44(3):367-72. PubMed ID: 26674803
[TBL] [Abstract][Full Text] [Related]
2. The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry: Results of an IQ DruSafe Minipig Survey.
Colleton C; Brewster D; Chester A; Clarke DO; Heining P; Olaharski A; Graziano M
Toxicol Pathol; 2016 Apr; 44(3):458-66. PubMed ID: 27006130
[TBL] [Abstract][Full Text] [Related]
3. The Use of Minipig in Drug Discovery and Development: Pros and Cons of Minipig Selection and Strategies to Use as a Preferred Nonrodent Species.
Heining P; Ruysschaert T
Toxicol Pathol; 2016 Apr; 44(3):467-73. PubMed ID: 26674804
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous background pathology in Göttingen minipigs.
Jeppesen G; Skydsgaard M
Toxicol Pathol; 2015 Feb; 43(2):257-66. PubMed ID: 24939892
[TBL] [Abstract][Full Text] [Related]
5. Gelucire and Gelucire-PEG400 formulations; tolerability in species used for non-clinical safety testing after oral (gavage) dosing.
Elander M; Boll JB; Hojman AS; Rasmussen AD
J Appl Toxicol; 2016 Nov; 36(11):1430-6. PubMed ID: 26849184
[TBL] [Abstract][Full Text] [Related]
6. Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility.
Gad SC; Spainhour CB; Shoemake C; Pallman DR; Stricker-Krongrad A; Downing PA; Seals RE; Eagle LA; Polhamus K; Daly J
Int J Toxicol; 2016; 35(2):95-178. PubMed ID: 26755718
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical vehicle use in studies by multiple routes in multiple species.
Gad SC; Cassidy CD; Aubert N; Spainhour B; Robbe H
Int J Toxicol; 2006; 25(6):499-521. PubMed ID: 17132609
[TBL] [Abstract][Full Text] [Related]
8. Oral toxicity of Miglyol 812(®) in the Göttingen(®) minipig.
Le Bars G; Dion S; Gauthier B; Mhedhbi S; Pohlmeyer-Esch G; Comby P; Vivan N; Ruty B
Regul Toxicol Pharmacol; 2015 Dec; 73(3):930-7. PubMed ID: 26408152
[TBL] [Abstract][Full Text] [Related]
9. The Potential of Minipigs in the Development of Anticancer Therapeutics: Species Comparison and Examples of Special Applications.
Mahl A; Dincer Z; Heining P
Toxicol Pathol; 2016 Apr; 44(3):391-7. PubMed ID: 26698323
[TBL] [Abstract][Full Text] [Related]
10. The minipig in toxicology.
Svendsen O
Exp Toxicol Pathol; 2006 Jul; 57(5-6):335-9. PubMed ID: 16725317
[TBL] [Abstract][Full Text] [Related]
11. A Brief Review of Infrequent Spontaneous Findings, Peculiar Anatomical Microscopic Features, and Potential Artifacts in Göttingen Minipigs.
McInnes EF; McKeag S
Toxicol Pathol; 2016 Apr; 44(3):338-45. PubMed ID: 26839330
[TBL] [Abstract][Full Text] [Related]
12. Is Science the Only Driver in Species Selection? An Internal Study to Evaluate Compound Requirements in the Minipig Compared to the Dog in Preclinical Studies.
Schaefer K; Rensing S; Hillen H; Burkhardt JE; Germann PG
Toxicol Pathol; 2016 Apr; 44(3):474-9. PubMed ID: 26839331
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis and transcriptional output of the Göttingen minipig genome.
Heckel T; Schmucki R; Berrera M; Ringshandl S; Badi L; Steiner G; Ravon M; Küng E; Kuhn B; Kratochwil NA; Schmitt G; Kiialainen A; Nowaczyk C; Daff H; Khan AP; Lekolool I; Pelle R; Okoth E; Bishop R; Daubenberger C; Ebeling M; Certa U
BMC Genomics; 2015 Nov; 16():932. PubMed ID: 26573612
[TBL] [Abstract][Full Text] [Related]
14. Suitability of a minipig model in assessing clinical bioperformance of matrix and multiparticulate extended-release formulations for a BCS class III Drug development candidate.
Kesisoglou F; Xie IH; Manser K; Wu Y; Hardy I; Fitzpatrick S
J Pharm Sci; 2014 Feb; 103(2):636-42. PubMed ID: 24382706
[TBL] [Abstract][Full Text] [Related]
15. Perspectives From the 12th Annual Minipig Research Forum: Early Inclusion of the Minipig in Safety Assessment Species Selection Should be the Standard Approach.
Jones K; Harding J; Makin A; Singh P; Jacobsen B; Mikkelsen LF
Toxicol Pathol; 2019 Oct; 47(7):891-895. PubMed ID: 31280706
[TBL] [Abstract][Full Text] [Related]
16. Validation of the normal, freely moving Göttingen minipig for pharmacological safety testing.
Markert M; Stubhan M; Mayer K; Trautmann T; Klumpp A; Schuler-Metz A; Schumacher K; Guth B
J Pharmacol Toxicol Methods; 2009; 60(1):79-87. PubMed ID: 19427912
[TBL] [Abstract][Full Text] [Related]
17. The minipig as nonrodent species in toxicology--where are we now?
Ganderup NC; Harvey W; Mortensen JT; Harrouk W
Int J Toxicol; 2012; 31(6):507-28. PubMed ID: 23134714
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach.
Lignet F; Sherbetjian E; Kratochwil N; Jones R; Suenderhauf C; Otteneder MB; Singer T; Parrott N
Pharm Res; 2016 Oct; 33(10):2565-79. PubMed ID: 27469324
[TBL] [Abstract][Full Text] [Related]
19. Utility of Göttingen minipigs for Prediction of Human Pharmacokinetic Profiles After Dermal Drug Application.
Yamamoto S; Karashima M; Sano N; Fukushi C; Tohyama K; Arai Y; Hirabayashi H; Amano N
Pharm Res; 2017 Nov; 34(11):2415-2424. PubMed ID: 28828717
[TBL] [Abstract][Full Text] [Related]
20. International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) for Lesions in the Minipig.
Skydsgaard M
Toxicol Pathol; 2016 Apr; 44(3):480-1. PubMed ID: 26534938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
